ERBB2 and breast cancer: After subtyping mammary tumors, 31 (48.4%) tumors were classified as luminal A, 14 (21.9%) as luminal B, 9 (14.1%) as triple-negative, and 10 (15.6%) as HER2-enriched (Table 2 and Figure 3(a)).